Positive subgroup analysis provides additional boost to Trius' skin infection antibiotic
This article was originally published in Scrip
Executive Summary
All eyes are now on Trius Therapeutics' second ongoing pivotal Phase III trial investigating its antibiotic, tedizolid phosphate, after the company reported positive, if disparate, results from a subgroup analysis of its first Phase III study (TR701-112) of the product in patients with acute bacterial skin and skin structure infections (ABSSSI).